PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer

Abstract

Background: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and the treatment effects are usually unsatisfactory. Vinorelbine (VRB) is extensively used in cancer treatment, but it has some disadvantages when used alone. PEGylated liposomes have been extensively used as a delivery carrier for antitumor drugs via prolonging the circulation time in the blood.

Purpose: The nanostructured liposomes were designed and prepared for treating NSCLC.

Methods: In the liposomes, PEG was modified on the liposomal surface, DC-Chol was used as cationic materials, and VRB plus quinacrine were encapsulated in an aqueous core of the liposomes as an antitumor drug and an apoptosis-inducing agent, respectively. Evaluations were performed on A549 cells, tubular network formations and xenografts of the A549 cells.

Results: The PEGylated drugs-loaded cationic liposomes could significantly enhance cellular uptake and selectively accumulate in A549 cells, thus leading to show strongest antitumor efficacy to tumor cells and to tumor-bearing mice. Action mechanisms showed that the enhanced efficacy in treating NSCLC was related to activate caspase 9 and caspase 3, to activate Bax and P53, and to suppress Bcl-2 and Mcl-1.

Conclusion: The PEGylated VRB plus quinacrine cationic liposomes showed a potential strategy for treating NSCLC.

• Liposomes
• solid tumor
• targeted drug delivery
• tumor targeting

Declaration of interest

The authors report that they have no conflicts of interest.

This work was supported by grants from the National Natural Science Foundation of China (No. 81102822).